Sustained long-term remissions with weekly interferon maintenance therapy in hairy cell leukemia

Asia-Pacific Journal of Clinical Oncology

Volumn 6, Issue 3, 2010, Pages 210-212

  Ramakrishna, Raj ^a   Manoharan, Arumugam ^a  

^a UNIVERSITY OF WOLLONGONG   (Australia)

Author keywords

Hairy cell leukemia; Interferon maintenance therapy

Indexed keywords

ALPHA2A INTERFERON;

ADULT; AGED; ARTICLE; CANCER REGRESSION; CLINICAL ARTICLE; DISEASE COURSE; DRUG EFFICACY; FEMALE; HAIRY CELL LEUKEMIA; HUMAN; MAINTENANCE THERAPY; MALE; PATIENT COMPLIANCE; PRIORITY JOURNAL; TREATMENT RESPONSE;

ADULT; AGED; ANTINEOPLASTIC AGENTS; FEMALE; HUMANS; INTERFERON ALFA-2A; LEUKEMIA, HAIRY CELL; MALE; MIDDLE AGED; REMISSION INDUCTION;

EID: 77956284096     PISSN: 17437555     EISSN: 17437563     Source Type: Journal    
DOI: 10.1111/j.1743-7563.2010.01295.x     Document Type: Article

References (16)

1. Golomb HM. Hairy cell leukemia: treatment success in the past 25 years. J Clin Oncol 2008, 26:2607-9.
2. Pileri S, Sabattini E, Poggi S. Bone marrow biopsy in hairy cell leukemia (HCL) patients, histological and immunohistological analysis of 46 cases treated with different therapies. Leuk Lymphoma 1994, 14:67-71.
3. Konwalinka G, Schirmer M, Hilbe W. Minimal residual disease in hairy cell leukaemia after treatment with 2′ chlorodeoxyadenosine. Blood Cells Mol Dis 1995, 21:142-51.
4. Mhawech-Fauceglia P, Oberholzer M, Aschenafi S, Baur A, Kurrer M, Von Rohr A. Potential predictive patterns of minimal residual disease detected by immunohistochemistry on bone marrow biopsy specimens during long-term follow-up in patients treated with cladribine for hairy cell leukaemia. Arch Pathol Lab Med 2006, 130:374-7.
5. Tallman MS. Current treatment strategies for patients with hairy cell leukemia. Rev Clin Exp Hematol 2002, 6:389-400.
6. Else M, Ruchlemer R, Osuji N. Long remissions in hairy cell leukaemia with purine analogs, a report of 219 patients with median follow-up of 12.5 years. Cancer 2005, 104:2442.
7. Vedantham S, Gamliel H, Golomb HM. Mechanism of interferon action in hairy cell leukemia; a model of effective cancer therapy. Cancer Res 1992, 52:1056-66.
8. Khalaf W, Maina C, Byers J, Harvey W. Interferon-alpha 2b and vesnarinone influence levels of tumor necrosis factor-alpha, apoptosis, or interleukin 6 in ESKOL, a hairy cell leukemic cell line. A potential cytokine and oncogene relationship regulating apoptosis is suggested. Leuk Res 2002, 26:169-77.
9. Damasio EE, Clavio M, Masoudi B. Alpha interferon therapy as induction and maintenance therapy in hairy cell leukaemia; long term follow-up analysis. Eur J Haematol 2000, 64:47-52.
10. Angelopoulou M, Anargyryou S, Sachanas S. Long term follow-up of hairy cell leukaemia patients treated with interferon-alpha. The importance of maintenance. Haematologica 2007, 92:42.
11. Benz R, Siciliano RD, Stussi G, Fehr J. Long-term follow-up of interferon-alpha induction and low-dose maintenance therapy in hairy cell leukaemia. Eur J Haematol 2009, 82:194-200.
12. Marotta G, Frassoldati A, Zinzani P. Role of interferon-alpha administration after 2-deoxycoformycin in the treatment of hairy cell leukaemia patients. Eur J Haematol 2006, 77:109-13.
13. Richards JM, Mick R, Latta JM. Serum soluble interleukin-2 receptor is associated with clinical and pathologic disease status in hairy cell leukaemia. Blood 1990, 76:1941-5.
14. Cervetti G, Galimberti S, Andreazzoli F. Rituximab as treatment for minimal residual disease in hairy cell leukaemia: extended follow-up. Br J Haematol 2008, 143:296-7.
15. Thomas DA, O'Brien S, Bueso-Ramos C, Faderl ST, Keating MJ, Giles FJ. Rituximab in relapsed or refractory hairy cell leukemia. Blood 2003, 102:3906-11.
16. Ravandi F, Jorgensen JL, O'Brien SM, Verstovsek SS, Koller CA, Faderl ST. Eradication of minimal residual disease in hairy cell leukemia. Blood 2006, 107:4658-62.